FAQ

EGFR NP_005219.2:p.K29_N298insG

Known as: EGFRvIII, Epidermal Growth Factor Receptor vIII, EGFR NP_005219.2:p.V30_R297delK29_N298insG 
A deletion of 268 amino acids of the epidermal growth factor receptor protein from the valine at position 30 through the arginine at position 297… (More)

Topic mentions per year

Topic mentions per year

1995-2017
020406019952017

Related topics

Related topics

2 relations
EGFR Gene Mutationepidermal growth factor receptor VIII

Related mentions per year

Related mentions per year

1995-2018
1990200020102020
EGFR NP_005219.2:p.K29_N298insG
epidermal growth factor receptor VIII
EGFR Gene Mutation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
PURPOSE Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
Human solid tumors frequently have pronounced heterogeneity of both neoplastic and normal cells on the histological, genetic, and… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers
Glioblastoma tumour cells release microvesicles (exosomes) containing mRNA, miRNA and angiogenic proteins. These microvesicles… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells
Aggressive human brain tumours (gliomas) often express a truncated and oncogenic form of the epidermal growth factor receptor… (More)
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target.
Glioblastoma is the most common primary malignant brain tumor of adults and one of the most lethal of all cancers. Patients with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
BACKGROUND The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed, or mutated in glioblastomas, but… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
BACKGROUND The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Glioblastoma multiforme (GBM) frequently involves amplification and alteration of the epidermal growth factor receptor (EGFR… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
1997
Highly Cited
1997
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated…
Deregulation of signaling by the epidermal growth factor receptor (EGFR) is common in human malignancy progression. One mutant… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Despite molecular biological advances in understanding human cancers, translation into therapy has been less forthcoming… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?